Ceryn Justyna, Lesiak Aleksandra, Sobolewska-Sztychny Dorota, Noweta Marcin, Ciążyńska Magdalena, Narbutt Joanna
Department of Dermatology, Paediatric Dermatology and Oncology Clinic, Medical University of Lodz, Poland.
Postepy Dermatol Alergol. 2025 Jan 31;42(3):221-231. doi: 10.5114/ada.2024.147331. eCollection 2025 Jun.
Actinic keratosis (AK) is a prevalent benign intraepidermal dysplasia, classified as squamous cell carcinoma (SCC ). Chronic ultraviolet (UV) light exposure is the primary etiological factor for AK, which predominantly manifests in sun-exposed areas. Management of AK emphasizes primary prevention through education, sun protection, and vigilant patient monitoring. Therapeutic strategies for AK are categorized into lesion-directed and field-directed approaches, encompassing topical treatments (imiquimod, 5-fluorouracil, diclofenac) and physical modalities (cryotherapy, photodynamic therapy, chemical peels, laser therapy, electrocoagulation, curettage). This comprehensive review discusses the current treatments and explores novel therapeutic options for AK.
光化性角化病（AK）是一种常见的良性表皮内发育异常，被归类为鳞状细胞癌（SCC）。长期紫外线（UV）暴露是AK的主要病因，主要表现在暴露于阳光下的部位。AK的管理强调通过教育、防晒和对患者的密切监测进行一级预防。AK的治疗策略分为针对病变和针对区域的方法，包括局部治疗（咪喹莫特、5-氟尿嘧啶、双氯芬酸）和物理治疗（冷冻疗法、光动力疗法、化学剥脱、激光治疗、电凝、刮除术）。这篇综述讨论了AK的当前治疗方法，并探索了新的治疗选择。
